hit counter
Aimmune Therapeutics, Inc. (AIMT) Stock News Sentiment & Price - Sentifly
AIMT - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aimmune Therapeutics, Inc. (AIMT)

USA
Biotechnology
NASDAQ
AIMT Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AIMT Latest news
Business Wire
Neutral
Aimmune to Present New Two-Year Treatment Satisfaction Data From Patients With Peanut Allergy at EAACI Hybrid Annual Congress 2021
2021-07-09 18:15

LONDON--(BUSINESS WIRE)--Aimmune Therapeutics UK Ltd., a Nestlé Health Science company developing and commercialising pharmaceutical therapies to prevent, manage, and treat food and metabolic related diseases, today announced it will present new treatment satisfaction data for its oral immunotherapy drug, PALFORZIA, at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2021 in Poland. The company will share updated treatment satisfaction data evaluated in its Phase

InvestorPlace
Positive
10 Best Stocks for 2020: Megatrends Support This Year's Biggest Winners
2020-10-21 12:54

Investors don't need a crystal ball to see how major trends in sectors such as e-commerce and biotech are supporting the best stocks in 2020. The post 10 Best Stocks for 2020: Megatrends Support This Year's Biggest Winners appeared first on InvestorPlace.

PRNewsWire
Neutral
Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Aimmune Therapeutics, Inc. In The Northern District Of California
2020-10-15 19:28

NEW YORK, Oct. 15, 2020 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Northern District of California, Case No. 4:20-cv-06733-YGR, on behalf of common shareholders of Aimmune...

GlobeNewsWire
Neutral
Nestlé completes acquisition of Aimmune Therapeutics
2020-10-14 01:15

Vevey, October 14, 2020

Reuters
Positive
Aimmune shareholders accept $2 billion Nestle tender offer
2020-10-13 01:39

Aimmune Therapeutics Inc shareholders have backed Nestle's $2 billion offer to gain full ownership of the first U.S.-approved peanut allergy treatment, which has struggled with a slow launch due to the COVID-19 pandemic.

GlobeNewsWire
Neutral
Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
2020-10-13 01:15

Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.

InvestorPlace
Positive
Best Stocks for 2020: Aimmune Therapeutics Gets Picked Up for a Steal
2020-10-05 09:00

Nestle picked my Best Stocks pick up for a steal, but I believe the decade of biotechnology is just now getting started. The post Best Stocks for 2020: Aimmune Therapeutics Gets Picked Up for a Steal appeared first on InvestorPlace.

Seeking Alpha
Neutral
Aimmune Therapeutics: Do Not Tender Your Shares To Nestle
2020-09-21 06:23

AIMT's stock fell precipitously amid the COVID-19 pandemic, despite receiving FDA approval for its Palforzia treatment (the first FDA approved treatment for peanut allergies).

PRNewsWire
Neutral
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics, Inc. - AIMT
2020-09-18 20:00

NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") (AIMT)...

GlobeNewsWire
Neutral
Nestlé commences tender offer for Aimmune Therapeutics, Inc.
2020-09-14 01:15

Vevey, September 14, 2020

Loading more news...